Early therapeutic efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (HCC) evaluated using contrast-enhanced Computed Tomography (CT) performed between 4 and 8 weeks after lenvatinib initiation according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and factors associated with efficacy.
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://figshare.com/articles/dataset/Early_therapeutic_efficacy_of_lenvatinib_in_patients_with_unresectable_hepatocellular_carcinoma_HCC_evaluated_using_contrast-enhanced_Computed_Tomography_CT_performed_between_4_and_8_weeks_after_lenvatinib_initiation_according_to_the_modifi/12112737
下载链接
链接失效反馈官方服务：
资源简介：
Early therapeutic efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (HCC) evaluated using contrast-enhanced Computed Tomography (CT) performed between 4 and 8 weeks after lenvatinib initiation according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and factors associated with efficacy.
创建时间：
2020-04-10
